---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-060816"
form_type: "8-K"
ticker: null
cik: "0001760173"
company_name: "SURGALIGN HOLDINGS, INC."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:56:31.119242+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surgalign sells Coflex/Cofix product lines to Xtant Medical for $17M cash

## Summary
- Sold 100% of Surgalign SPV equity to Xtant Medical for $17M cash.
- Transaction closed Feb 28, 2023; includes Coflex/Cofix product lines and worldwide IP.
- Pro forma shows removal of ~$10.9M revenue (9M 2022) and ~$17.8M (FY2021).
- Estimated gain on disposal of $13.5M recorded in pro forma; actual gain in Q1 2023.
- Transition services agreement signed for post-closing support.

## SEC filing metadata
- accession: 0001193125-23-060816
- form_type: 8-K
- cik: 0001760173
- company_name: SURGALIGN HOLDINGS, INC.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/d439544d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-060816
- JSON: https://secwatch.observer/filing/0001193125-23-060816.json
- Plain text: https://secwatch.observer/filing/0001193125-23-060816.txt

## Key facts
- M&A Transactions
  SURGALIGN HOLDINGS, INC. completed a disposition involving Xtant Medical Holdings, Inc. for $17.0 million in cash (closed 2023-02-28).
  - Action: disposition
  - Counterparty: Xtant Medical Holdings, Inc.
  - Consideration: $17.0 million in cash
  - Closing: 2023-02-28
  source text: the aggregate consideration paid in the Coflex Transaction for 100% of Surgalign SPV's equity securities was $17.0 million in cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm
- Material Agreements
  SURGALIGN HOLDINGS, INC. entered into Transition Services Agreement with Xtant Medical Holdings, Inc. (effective 2023-02-28).
  - Action: entry
  - Counterparty: Xtant Medical Holdings, Inc.
  - Effective: 2023-02-28
  source text: Seller, Surgalign SPV and Xtant also entered into a Transition Services Agreement, dated as of February 28, 2023 (the “Transition Services Agreement”), in connection with the Coflex Transaction pursuant to which Seller has agreed to provide certain transition services to Xtant immediately after the closing for an agreed upon transition period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm
- Material Agreements
  SURGALIGN HOLDINGS, INC. entered into Equity Purchase Agreement with Xtant Medical Holdings, Inc. valued at $17.0 million (effective 2023-02-28).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Xtant Medical Holdings, Inc.
  - Value: $17.0 million
  - Effective: 2023-02-28
  source text: ., a Delaware corporation (“Surgalign SPV”) an indirect subsidiary of Surgalign Holdings, Inc., a Delaware corporation (the “Company”), Surgalign Spine Technologies, Inc, a Delaware corporation and sole stockholder of Surgalign SPV (“Seller”), the Company and Xtant Medical Holdings, Inc., a Delaware corporation (“Xtant” or “Buyer”) entered into an Equity Purchase Agreement (the “Coflex Purchase Agreement”), pursuant to which, among other things and concurrently with execution thereof, Xtant acquired 100% of the issued and outstanding equity of Surgalign SPV, from Seller (the “Coflex Transaction”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1760173/000119312523060816/0001193125-23-060816-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.